[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591377":3},{"organization":4,"outcomesModule":7,"designInfo":43,"detailedDescription":11,"studyPopulation":11,"armGroups":49,"interventions":56,"overallOfficials":60,"centralContacts":65,"locations":71,"responsibleParty":91,"collaborators":11,"id":93,"slug":11,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":11,"studyType":105,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":113,"whyStopped":11,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Rabin Medical Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"Sensor glucose percentage of time in range (70-180 mg\u002Fdl)",null,"At the end of the 12 weeks intervention period",[14,16,18,20],{"measure":15,"description":11,"timeFrame":12},"Percentage of sensor glucose readings \u003C54 mg\u002Fdl",{"measure":17,"description":11,"timeFrame":12},"Percentage of sensor glucose readings >180 mg\u002Fdl",{"measure":19,"description":11,"timeFrame":12},"Percentage of sensor glucose readings >250 mg\u002Fdl",{"measure":21,"description":11,"timeFrame":12},"HbA1c",[23,25,27,29,31,33,35,37,39,41],{"measure":24,"description":11,"timeFrame":12},"Serious Adverse Events (SAE)",{"measure":26,"description":11,"timeFrame":12},"Diabetic Ketoacidosis (DKA) events",{"measure":28,"description":11,"timeFrame":12},"Severe Hypoglycemia events",{"measure":30,"description":11,"timeFrame":12},"Percentage of sensor glucose readings in the range 70 to 140 mg\u002FdL",{"measure":32,"description":11,"timeFrame":12},"Percentage of sensor glucose readings in the range 70 to 180 mg\u002FdL",{"measure":34,"description":11,"timeFrame":12},"Percentage of sensor glucose readings >180 mg\u002FdL",{"measure":36,"description":11,"timeFrame":12},"CGM derived indices- Mean glucose",{"measure":38,"description":11,"timeFrame":12},"CGM derived indices: Coefficient of variation",{"measure":40,"description":11,"timeFrame":12},"CGM derived indices: Peak glucose and change in glucose from the start of the meal to the peak (only calculated for post-meal periods)",{"measure":42,"description":11,"timeFrame":12},"CGM derived indices: change in glucose from the start of the exercise to the nadir.",{"allocation":44,"interventionModel":45,"interventionModelDescription":11,"primaryPurpose":46,"observationalModel":11,"timePerspective":11,"maskingInfo":47},"NA","SINGLE_GROUP","TREATMENT",{"masking":48,"maskingDescription":11,"whoMasked":11},"NONE",[50],{"label":51,"type":52,"description":53,"interventionNames":54},"Tandem Mobi Hybrid Closed Loop (HCL) pump","EXPERIMENTAL","Tandem Mobi Hybrid Closed Loop (HCL) pump with an integrated Control-IQ algorithm (CIQ), the Dexcom G7 continuous glucose monitoring sensor (CGM ) and Tandem Mobi Mobile App",[55],"Device: Tandem Mobi Hybrid Closed Loop (HCL) pump",[57],{"type":58,"name":51,"description":53,"armGroupLabels":59,"otherNames":11},"DEVICE",[51],[61],{"name":62,"affiliation":63,"role":64},"Marie Muller, MD","Schneider Children's Medical Center","PRINCIPAL_INVESTIGATOR",[66],{"name":67,"role":68,"phone":69,"phoneExt":11,"email":70},"Alona Hamou, Msc","CONTACT","972-545-950277","alonah@clalit.org.il",[72],{"facility":73,"status":11,"city":74,"state":11,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":84},"Schneider Children's Medical Center of Israel","Petah Tikva","4920235","Israel","IL",{"type":79,"coordinates":80},"Point",[81,82],34.88747,32.08707,{"lat":82,"lon":81},[85,88],{"name":86,"role":68,"phone":87,"phoneExt":11,"email":70},"Alona Hamou, MSc","972-3-9253282",{"name":89,"role":90,"phone":11,"phoneExt":11,"email":11},"Revital Nimri, MD","SUB_INVESTIGATOR",{"type":92,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100591377",false,"NCT06979635","Assessing the Safety, Performance, and User Experience of the Tandem Mobi Automated Insulin Delivery System Among Young Competitive Athletes in Real-world Settings.","Captain MOBI","Inclusion Criteria:\n\n* Type 1 diabetes (T1D) for at least 6 months\n* 11≤Age≤18 years\n* HbA1c \\\u003C10.0%\n* Current treatment with automated insulin delivery system (AID) or insulin pump for at least 1 month\n* Willing to switch to Tandem Mobi Pump System and Dexcom CGM for the study duration\n* Competitive-level athletes\n\nExclusion Criteria:\n\n* Concomitant disease that influences metabolic control or HbA1c interpretation\n* Individual has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection)\n* Use of antidiabetic agents other than insulin\n* Two or more episodes of severe hypoglycemia (hypoglycemia requiring treatment by another person) within the previous 6 months\n* One or more episodes of ketoacidosis requiring hospitalization within 6 months prior to screening\n* Individual has a positive pregnancy screening test","ALL","11 Years","18 Years",{"count":103,"type":104},12,"ESTIMATED","INTERVENTIONAL",[44],"A single arm, interventional study with 12 weeks study phase preceded by a 2-week run in phase, aiming to evaluate the effectiveness and applicability of the Tandem Mobi automated insulin delivery system (Tandem Mobi Pump System) for competitive youth athletes with type 1 diabetes in real-world conditions.",[109],"Type 1 Diabetes",[109,111,112],"Competitive athletes","Hybrid Closed Loop System","NOT_YET_RECRUITING","2025-05-21",{"date":116,"type":117},"2025-05-25","ACTUAL",{"date":119,"type":104},"2025-06",{"date":119,"type":104},{"name":5,"class":6},1]